Acetylsalicylic Acid
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Acetylsalicylic Acid
- Pharmacist Assessment Report
- Acetylsalicylic acid: Cyclooxygenase-inhibiting antiplatelet and anti-inflammatory agent → atrophoderma vermiculata
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Acetylsalicylic acid: Cyclooxygenase-inhibiting antiplatelet and anti-inflammatory agent → atrophoderma vermiculata
One-Sentence Summary
Acetylsalicylic acid (aspirin) is a long-established oral drug that inhibits cyclooxygenase. The TxGNN model predicts it may be relevant to atrophoderma vermiculata, a rare skin disorder, with a prediction score of 0.9959. No clinical trials or publications were found for this prediction, so it rests on computation alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | atrophoderma vermiculata |
| TxGNN Prediction Score | 0.9959 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for this drug were not available in the data compiled for this report. Aspirin is generally known to block cyclooxygenase enzymes, which reduces prostaglandin and thromboxane production and gives it antiplatelet, analgesic and anti-inflammatory effects.
The data compiled for this report did not identify any mechanistic rationale linking these actions to atrophoderma vermiculata. This condition is a rare follicular and atrophic skin disorder. The high score is a computational output only. It is not supported by any trial, case series or publication retrieved for this report, and the similarity to the drug’s established uses has not been assessed.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Aspirin-containing products are currently marketed in India, and all licences in the local data are valid. These are oral products (capsules and tablets). The local records contain no approved-indication text.
Safety Considerations
- Drug Interactions: The data compiled for this report contain 657 recorded interactions. Examples rated Major include:
- acalabrutinib
- acetazolamide
- ketorolac
- ibuprofen
- fondaparinux
- trastuzumab emtansine
Examples rated Moderate include:
- abciximab
- nifedipine
- hydrocortisone
- ethanol
- alendronic acid
- fluvoxamine
Bleeding risk with other antithrombotic or anti-inflammatory agents is the main theme.
Package insert warnings and contraindications were not retrieved. Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The prediction has a high model score but no supporting trials, literature or mechanistic rationale, so it stays at evidence level L5.
To proceed, the following is needed:
- Mechanism of action data and a plausible biological link to atrophoderma vermiculata
- Any case reports, preclinical work or other studies that directly address this condition
- Package insert warnings and contraindications for the marketed products
- An assessment of whether an oral antiplatelet or anti-inflammatory drug is a suitable route for a skin condition, with a bleeding-risk review
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.